La Jolla Institute for Allergy and Immunology

A La Jolla Institute for Allergy and Immunology-led team sequenced the transcriptomes of thousands of CD4+ T cells and compared their expression patterns.

The Human Immunome Program, which is part of the Human Vaccines Project, eventually plans to profile B-cell and T-cell receptors in more than 1,000 individuals.

LIAI is preparing to assemble a permanent staff to run the screening facility, which is expected to include a manager and two full-time technicians, as well as a center director.

If MedImmune can develop and market a drug based on the discovery, it could be a financial boost to the institute, which hopes to diversify its revenue sources once cash from sole corporate sponsor Kirin Pharma USA dries up in 2010.

The US Food and Drug Administration has approved Alnylam's RNAi-based therapy Onpattro, according to Stat News.

Harvard Medical School's Seth Cassel and Cigall Kadoch argue in a Baltimore Sun op-ed that the recent TAILORx trial shows the potential of genomic-based medicine.

Researchers in the UK are working on using gene drives to control malaria-carrying mosquitoes, the Telegraph reports.

In PLOS this week: genetic architecture mediating gene expression, metabolomic patterns in multiple myeloma, and more.